Piritrexim
Piritrexim (BW 301U) is a potent dihydrofolate reductase (DHFR) inhibitor against Pneumocystis carinii and Toxoplasma gondii, with IC50 values of 0.038 and 0.011 μM, respectively. Piritrexim can be used for acquired immune deficiency syndrome (AIDS) research. Piritrexim also is an anticancer agent[1].
Product Specifications
CAS Number
[72732-56-0]
Product Name Alternative
BW 301U; NSC 351521
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Dihydrofolate reductase (DHFR)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/piritrexim.html
Purity
99.68
Smiles
CC1=C(CC2=C(C=CC(OC)=C2)OC)C=NC3=NC(N)=NC(N)=C13
Molecular Formula
C17H19N5O2
Molecular Weight
325.37
Precautions
H302, H315, H319, H335
References & Citations
[1]Rosowsky A, et al. 2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J Med Chem. 1993 Oct 15;36 (21) :3103-12. |[2]Zink M, et al. Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling investigations. Eur J Med Chem. 2004 Dec;39 (12) :1079-88.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
037931-AP 200 µL
LRIT1, CT (LRIT1, LRRC21, PAL, Leucine-rich repeat, immunoglobulin-like domain and transmembrane domain-containing protein 1, Leucine-rich repeat-containing protein 21, Photoreceptor-associated LRR superfamily protein, Retina-specific protein PAL) (AP) discontinued
Ask
View Details